Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

Vancomycin remains the mainstay treatment for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) despite increased treatment failures. Daptomycin has been shown to improve clinical outcomes in patients with BSIs caused by MRSA isolates with vancomycin MICs of >1 mg/l...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Claeys, Kimberly C., Zasowski, Evan J., Casapao, Anthony M., Lagnf, Abdalhamid M., Nagel, Jerod L., Nguyen, Cynthia T., Hallesy, Jessica A., Compton, Mathew T., Kaye, Keith S., Levine, Donald P., Davis, Susan L., Rybak, Michael J.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2016
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038271/
https://ncbi.nlm.nih.gov/pubmed/27431221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00227-16
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires